VALUE DEMONSTRATION OF IMMUNO-ONCOLOGY THERAPIES IN A RARE TUMOR COMPARING ASCO, NCCN, AND TRADITIONAL COST-EFFECTIVENESS ANALYSIS

Garmo V; Ambavane A.; Lanitis T.; Kongnakom T.; Phatak H.

首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >VALUE DEMONSTRATION OF IMMUNO-ONCOLOGY THERAPIES IN A RARE TUMOR COMPARING ASCO, NCCN, AND TRADITIONAL COST-EFFECTIVENESS ANALYSIS

【24h】

VALUE DEMONSTRATION OF IMMUNO-ONCOLOGY THERAPIES IN A RARE TUMOR COMPARING ASCO, NCCN, AND TRADITIONAL COST-EFFECTIVENESS ANALYSIS

机译：罕见肿瘤中免疫肿瘤疗法的价值展示比较ASCO，NCCN和传统成本效益分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2017年第5期|共2页
作者
Garmo V; Ambavane A.; Lanitis T.; Kongnakom T.; Phatak H.;
展开▼
作者单位

EMD Serono Inc Rockland MA USA;

Evidera London England;

Evidera London England;

Evidera London England;

EMD Serono Inc Rockland MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. VALUE DEMONSTRATION OF IMMUNO-ONCOLOGY THERAPIES IN A RARE TUMOR COMPARING ASCO, NCCN, AND TRADITIONAL COST-EFFECTIVENESS ANALYSIS [J] . Garmo V, Ambavane A., Lanitis T., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：罕见肿瘤中免疫肿瘤疗法的价值展示比较ASCO，NCCN和传统成本效益分析
2. Correction: Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer,Decision analytic cost-effectiveness model to compare prostate cryotherapy to andro [J] . BMJ Open . 2016,第8期

机译：更正：比较前列腺冷冻疗法与雄激素剥夺疗法治疗放射复发性前列腺癌的决策分析成本效益模型，比较前列腺冷冻疗法与雄激素比较的决策分析成本效益模型
3. Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial [J] . Papazoglou Despoina, Lesnick Connie E., Wang Victoria, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：基于Ibrutinib的疗法改善了抗肿瘤T细胞杀伤功能，允许与传统的FCR化疗相比，抗PD-L1免疫疗法进行有效配对; 来自III期E1912试验的治疗和相关免疫功能数据的影响
4. Comparing QUS parameters to structural and functional changes in tumors during therapy [C] . Alexandre Dizeux, Delphine Le Guillou-Buffelo, Lori Bridal, IEEE International Ultrasonics Symposium . 2016

机译：比较QUS参数与治疗期间肿瘤的结构和功能变化
5. A cost-effectiveness analysis of anthelminthic intervention for community control of ascariasis: Traditional vs. pharmaceutical therapy. [D] . Ortega, Fernando. 2000

机译：community虫病社区控制as虫病的成本效益分析：传统疗法与药物疗法。
6. BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer [O] . Jan Norum, Eli Marie Grindedal, Cecilie Heramb, 2018

机译：BRCA突变携带者检测。基于模型的成本效益分析将传统的家族史方法与所有乳腺癌患者的测试进行比较
7. 174 An ex vivo tumoroid model of fresh patient tumors (3D-ACT) to assess efficacy of cellular therapy in immuno-oncology [O] . Stephen Iwanowycz, Jared Ehrhart, Mibel Pabon, 2020

机译：174新款患者肿瘤（3D-ACT）的前体内肿瘤模型评估细胞治疗在免疫肿瘤中的疗效
8. Measuring and Comparing the Cost-Effectiveness of EPA Regulatory Efforts to Control Toxics-Related Health Risks. Volume II: Cost-Effectiveness Analysis of EPA Intermedia Priority Pollutants [R] . 1981

机译：测量和比较Epa监管努力的成本效益，以控制与有毒有关的健康风险。第二卷：Epa中间层优先污染物的成本效益分析

VALUE DEMONSTRATION OF IMMUNO-ONCOLOGY THERAPIES IN A RARE TUMOR COMPARING ASCO, NCCN, AND TRADITIONAL COST-EFFECTIVENESS ANALYSIS

著录项

相似文献

相关主题

期刊订阅